N E W S
17 November 2021
Dutch stem cell biotech Neuroplast secures € 10 million (US$ 11.5 million) in Series B funding to further advance its transformative stem cell therapy for Traumatic Spinal Cord Injury.
09 November 2021
Dutch stem cell biotech Neuroplast announces successful clinical Phase I trial with its Neuro-Cells® stem cell treatment for Traumatic Spinal Cord Injury.
21 October 2021
Dutch stem cell biotech Neuroplast appoints TiGenix founder Frank Luyten and Sanquin director Pieter
de Geus to its supervisory board.
19 November 2020
Neuro-Cells® in patient. Neuroplast BV announced the first patient with chronic spinal cord injury was treated with Neuro-Cells®.
18 February 2020
Neuroplast raises € 4 million for its stem cell-based technology to treat patients with Spinal Cord Injury.
01 May 2019
European Medicines Agency (EMA) has granted Orphan Drug Designation to Neuroplast treatment.